Compare AMRC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | PGEN |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2010 | 2013 |
| Metric | AMRC | PGEN |
|---|---|---|
| Price | $26.77 | $5.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $37.88 | $8.33 |
| AVG Volume (30 Days) | 569.5K | ★ 5.5M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,769,928,000.00 | $230,981,000.00 |
| Revenue This Year | $10.71 | $1,115.92 |
| Revenue Next Year | $9.07 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 28.76 | N/A |
| 52 Week Low | $14.88 | $1.40 |
| 52 Week High | $44.93 | $5.68 |
| Indicator | AMRC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 76.36 |
| Support Level | $24.44 | $3.90 |
| Resistance Level | $27.25 | N/A |
| Average True Range (ATR) | 1.67 | 0.33 |
| MACD | -0.20 | 0.15 |
| Stochastic Oscillator | 32.62 | 89.96 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.